Pulmonary Vascular Disease Section
-
Navigating PE treatment: What AHA/ACC guidelines recommend
New AHA/ACC guidelines on acute PE care expand the recommended scope of catheter-based interventions for patients at increased risk of clinical deterioration and provide an in-depth discussion of the role of reperfusion therapies to treat PE.
-
Small steps toward a noninvasive approach to pulmonary hypertension
Noninvasive imaging approaches, particularly echocardiography-based and CT scan-based main pulmonary artery diameter assessment, offer complementary insights into early PH detection and risk stratification.
-
Shared decision-making in PAH
Shared decision-making is a collaborative process where clinicians and patients make informed health care decisions together, balancing medical evidence with patient values, which is especially important in complex conditions like PAH.
-
Major takeaways from the seventh world symposium on PH
The core definition of pulmonary hypertension (PH) remains a mean pulmonary arterial pressure (mPAP) > 20 mm Hg, with precapillary PH defined by a pulmonary arterial wedge pressure (PCWP) ≤ 15 mm Hg and pulmonary vascular resistance (PVR) > 2 Wood units (WU), similar to the 2022 European guidelines.1 2 There was recognition of uncertainty…
-
Right heart catheterization practice patterns in pulmonary hypertension in the US
In the right clinical scenario, three key hemodynamic components obtained by right heart catheterization (RHC) define precapillary pulmonary hypertension (PH) warranting vasodilator treatment: mean pulmonary arterial pressure >20 mm Hg, pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg, and pulmonary vascular resistance (PVR) >2Wood units.1 While these cutoffs are straightforward, a gap in practical application…
